Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The company uses iPS cells to develop treatments for diseases relating to the kidney
Subscribe To Our Newsletter & Stay Updated